Donna O Bunch
Affiliation: University of North Carolina
- Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximabDonna O Dell Bunch
UNC Kidney Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Clin J Am Soc Nephrol 8:382-91. 2013..To avoid infections and adverse events from therapy, clinicians require improved markers of disease activity and impending relapse to guide immunosuppression strategies after rituximab treatment...
- Maintenance of tolerance by regulation of anti-myeloperoxidase B cellsDonna O Bunch
UNC Kidney Center, Department of Medicine, Division of Nephrology and Hypertension, University of North Carolina, 5005 Burnett Womack, Campus Box 7155, Chapel Hill, NC 27599, USA
J Am Soc Nephrol 19:1763-73. 2008..A defect in these regulatory pathways could result in autoimmune disease...
- Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitisJulieanne G McGregor
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Nephrol Dial Transplant 30:i123-i131. 2015..Rituximab has been used in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) since 2003. Our objective was to describe outcomes and adverse events following rituximab since that time in an inception cohort...
- Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance lossDonna A Culton
Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
J Clin Immunol 27:53-68. 2007..These findings have implications for autoreactive B-cell activation and suggest a shared mechanism of B-cell tolerance loss in these two diseases...